Modern Chinese Medicine Group Reports 15.4% Revenue Decline, Swings to RMB2.5 Million Profit, EPS Improves to RMB0.41 Cents

Reuters
08/29
Modern Chinese Medicine Group Reports 15.4% Revenue Decline, Swings to RMB2.5 Million Profit, EPS Improves to RMB0.41 Cents

Modern Chinese Medicine Group Co. Ltd. has released its interim results for the six months ended 30 June 2025. The company reported a revenue decrease of approximately 15.4%, dropping from RMB76.6 million in the previous period to RMB64.8 million in the current period. Despite the decline in revenue, the company recorded a shift from a loss of RMB6.9 million in the previous period to earnings of RMB2.5 million for the current period. This improvement in profitability is also reflected in the earnings per share, which turned from a loss of RMB1.14 cents to earnings of RMB0.41 cents. The gross profit also saw a decrease of approximately 25.3%, falling from RMB21.7 million to RMB16.2 million. The company managed to improve its profit before tax, reporting a figure of RMB3.43 million compared to a loss of RMB4.33 million in the previous period. Additionally, other income, gains, and losses netted RMB1.41 million, a significant improvement from a loss of RMB8.41 million in the previous period. No specific updates regarding the company's business operations or future outlook were provided in the interim results announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Chinese Medicine Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10